Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is widely recognized as a potentially severe toxicity that often leads to dose reduction or discontinuation of cancer treatment. Symptoms may persist despite discontinuation of chemotherapy and quality of life can be severely compromised. The clinical symptoms of CIPN, and the cellular and molecular targets involved in CIPN, are just as diverse as the wide variety of anticancer agents that cause peripheral neurotoxicity. There is an urgent need for extensive molecular and functional investigations aimed at understanding the mechanisms of CIPN. Furthermore, a reliable human cell culture system that recapitulates the diversity of neuronal modalities found in vivo and the pathophysiological changes that underlie CIPN would serve to advance the understanding of the pathogenesis of CIPN. The demonstration of experimental reproducibility in a human peripheral neuronal cell system will increase confidence that such an in vitro model is clinically useful, ultimately resulting in deeper exploration for the prevention and treatment of CIPN. Herein, we review current in vitro models with a focus on key characteristics and attributes desirable for an ideal human cell culture model relevant for CIPN investigations.

Highlights

  • Chemotherapy-induced peripheral neuropathy (CIPN) is an adverse consequence of a wide variety of commonly used anticancer agents [1,2,3,4,5,6,7,8,9] and there are no gold standard therapeutics recommended for the prevention or treatment of CIPN [10]

  • A common pathology in CIPN is a “dying back” axon degeneration of distal nerve endings [9,19]. While it is not within the scope of this paper to review the pathogenesis of CIPN, readers are referred to several excellent and comprehensive reviews of the possible mechanisms involved in CIPN [8,16,20]

  • This review aims to focus on key characteristics and attributes desirable for an ideal human cell culture model of CIPN

Read more

Summary

Introduction

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. A common pathology in CIPN is a “dying back” axon degeneration of distal nerve endings [9,19] While it is not within the scope of this paper to review the pathogenesis of CIPN, readers are referred to several excellent and comprehensive reviews of the possible mechanisms involved in CIPN [8,16,20]. In this present paper, examples of agents that cause CIPN and can be used as tool compounds for the development of an in vitro model are provided to highlight the key features required for an in vitro cell model system designed to interrogate the pathogenesis of CIPN.

Anticancer Agents That Cause CIPN
In Vitro Models
Morphologic Features
Gene Expression
Protein Expression
Functional Analysis
High-Content Analysis
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call